JTT 551 is selective a protein tyrosine phosphatase 1B ( PTP1B ) inhibitor, with K i s of 0.22 μM and 9.3 μM for PTP1B and TCPTP (T-cell protein tyrosine phosphatase), respectively; JTT 551 can be used in the research of type 2 diabetes mellitus.
In Vitro
JTT 551 is selective a protein tyrosine phosphatase 1B (PTP1B) inhibitor, with K i s of 0.22 μM and 9.3 μM for PTP1B and TCPTP (T-cell protein tyrosine phosphatase), respectively. JTT 551 shows low affinity at CD45 PTP (CD45) and leucocyte common antigen-related (LAR) PTP with K i s of both >30 μM. Furthermore, JTT-551 (10 and 30 μM) enhances the insulin-induced deoxyglucose uptake in a dosedependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JTT 551 (3 mg/kg, 30 mg/kg, p.o.) dose-dependently decreases blood glucose level on Days 7, 14 and 28 in db/db Mice. JTT 551 also significantly reduces triglyceride (TG) level at 30 mg/kg on Day 7 but does not alter insulin and total cholesterol (TC) levels .They are for reference only.
Form:Solid
规格
英文别名
2-(((5-(tert-Butyl)thiazol-2-yl)methyl)((4-(4-((4-(heptan-4-yl)phenoxy)methyl)phenyl)thiazol-2-yl)methyl)amino)acetic acid | GLYCINE, N-((5-(1,1-DIMETHYLETHYL)-2-THIAZOLYL)METHYL)-N-((4-(4-((4-(1-PROPYLBUTYL)PHENOXY)METHYL)PHENYL)-2-THIAZOLYL)METHYL)- | H
规格或纯度
Moligand™, ≥99%
英文名称
JTT 551
生化机理
JTT 551 是一种选择性的蛋白酪氨酸磷酸酶 1B (PTP1B)抑制剂,对 PTP1B 和 TCPTP(T 细胞蛋白酪氨酸磷酸酶)的 K i s 分别为 0.22 μM 和 9.3 μM;JTT 551 可用于 2 型糖尿病的研究。